Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

分组1 - Arbutus Biopharma reported a quarterly loss of $0.10 per share, which is in line with the Zacks Consensus Estimate, and an improvement from a loss of $0.12 per share a year ago [1] - The company posted revenues of $1.34 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 22.82%, and a significant decline from year-ago revenues of $4.66 million [2] - Over the last four quarters, Arbutus has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2][1] 分组2 - Arbutus shares have increased approximately 58.4% since the beginning of the year, outperforming the S&P 500's gain of 21.2% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for future stock performance [4] - The current consensus EPS estimate for the coming quarter is -$0.09 on revenues of $1.76 million, and for the current fiscal year, it is -$0.38 on revenues of $7.35 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Arbutus belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Arbutus's stock performance [5] - The current estimate revisions trend for Arbutus is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]